TLSA — Tiziana Life Sciences Ltd

Nasdaq · Health Care · Pharmaceuticals · CIK 1723069 ·
Last close
$1.23
Market Cap
$156.53M
52W High
$1.85
52W Low
$1.04
ADV30
202,835
Next earnings
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Dec 2025 11,495,000 4,010,000 11,443,000
Dec 2024 11,284,000 3,724,000 7,348,000

Balance + Analyst (yfinance extras)

Retained Earnings
$-144,831,000
Inventory
Receivables
$3,692,000
ST Investments
EBIT TTM
Pretax Income TTM
Interest Exp TTM
Analysts
1

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -21,132,000 -18,431,000 11,495,000 11,443,000 -12,847,000
Dec 2024 0 -15,794,000 -11,863,000 11,284,000 7,348,000 -1,526,000
Dec 2023 0 -17,984,000 -17,691,000 12,184,000 6,648,000 -15,698,000
Dec 2022 0 -14,586,000 -15,397,000 26,477,000 6,906,000 -19,615,000
Dec 2021

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.20

Peers — same industry

TickerNameMarket CapLastDaily %
CNTB Connect Biopharma Holdings Ltd $158.04M $2.51
KZIA KAZIA THERAPEUTICS LTD $154.95M $13.56
CUE Cue Biopharma, Inc. $154.49M $36.78
SMNR Semnur Pharmaceuticals, Inc. $158.84M $0.69
MIST Milestone Pharmaceuticals Inc. $159.36M $1.28

News headlines (Yahoo Finance, 1h cache)

Tiziana Life Sciences doses last patient in Phase 2a multiple sclerosis trial
2026-06-25 13:05 · Yahoo
Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial
2026-06-25 11:00 · Yahoo
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
2026-06-15 11:00 · Yahoo
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More
2026-05-29 22:55 · Yahoo
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York
2026-05-28 11:00 · Yahoo
Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMI
2026-05-22 20:48 · Yahoo
Tiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trial
2026-05-21 15:44 · Yahoo
Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial
2026-05-21 15:00 · Yahoo
Sector Update: Healthcare Stocks Gain Late Afternoon
2026-05-19 19:55 · Yahoo
Tiziana Life Sciences price target boosted on foralumab update
2026-05-19 19:12 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.